Essential fatty acids and the brain

Canadian Journal of Psychiatry

Volumn 48, Issue 3, 2003, Pages 195-203

  Haag, Marianne ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Depression; Mental performance; Neurotransmission; Omega 3 fatty acids; Phospholipase A2; Polyunsaturated fatty acids; Prostaglandins; Schizophrenia

Indexed keywords

ESSENTIAL FATTY ACID; MEMBRANE PHOSPHOLIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPASE A2; PROSTAGLANDIN DERIVATIVE;

BRAIN DYSFUNCTION; BRAIN FUNCTION; BRAIN MEMBRANE; CATECHOLAMINERGIC SYSTEM; DIETARY INTAKE; FATTY ACID DESATURATION; HUMAN; LIPID COMPOSITION; MENTAL DISEASE; NERVE CELL MEMBRANE; NONHUMAN; RAT; REVIEW; SEROTONINERGIC TRANSMISSION;

EID: 0038292118     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304800308     Document Type: Review

References (99)

1. Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res 1999;56:565-70.
2. Bourre JM, Francois M, Youyou A, Dumont O, Piciotti M, Pascal G, and others The effects of dietary α-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats. J Nutr 1989;119:1880-92.
3. Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res 1985;24:69-176.
4. Martin RE, Bazan NG. Changing fatty acid content of growth cone lipids prior to synaptogenesis. J Neurochem 1992;59:318-25.
5. Green P, Glozman S, Kamensky B, Yavin E. Developmental changes in rat membrane lipids and fatty acids: the preferential prenatal accumulation of DHA. J Lipid Res 1999;40:960-6.
6. Jones CR, Arai T, Rapoport SI. Evidence for the involvement of docosahexanoic acid in cholinergic stimulated signal transduction art the synapse. Neurochem Res 1997;22:663-70.
7. Lauritzen L, Hansen HS, Jørgensen MH, Michaelsen KF. The essentiality of long-chain omega-3 fatty acids in relation to development and function of the brain and retina. Prog Lip Res 2001;40:1-94.
8. Martinez M. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res 1992;583:171-82.
9. Haggarty P, Ashton J, Joynson M, Abramovich DR, Page K. Effect of maternal poly-unsaturated fatty acid concentration on transport by the human placenta. Biol Neonate 1999;75:350-9.
10. Birch EE, Hoffmann DR, Uauy R, Birch DG, Prestidge C. Visual acuity and the essentiality of docosahexanoic acid and arachidonic acid in in the diet of term infants. Pediatr Res 1998;44:201-9.
11. Neuringer M. Cerebral cortex docosahexanoic acid is lower in formula-fed than in breast-fed infants. Nutr Rev 1993;51:238-41.
12. Birch EE, Garfield S, Hoffmann DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long-chain poly-unsaturated fatty acids and mental development in term infants. Dev Med Child Neurol 2000;42:174-81.
13. Jamieson EC, Farquarson J, Logan RW, Howatson AG, Patrick WJ, Weaver LT, and others. Infant cerebellar grey and white matter fatty acids in relation to age and diet. Lipids 1999;34:1065-71.
14. Salem N, Ward GR. Are omega-3 fatty acids essential nutrients for animals? World Rev Nutr Diet 1993;72:128-47.
15. Chamberlain JG. Fatty acids in human brain phylogeny. Perspect Biol Med 1996;39:436-45.
16. Broadhurst CL, Cunnane SC, Crawford MA. Rift valley lake fish and shellfish provided brain-specific nutrition for early Homo. Br J Nutr 1998;79:3-21.
17. Mayes PA. Metabolism of unsaturated fatty acids and eicosanoids. In: Murray RK, Granner DK, Mayes PA, Rodwell VW, editors. Harper's biochemistry. 24th ed. London: Prentice Hall; 1996. p 236-44.
18. Haag M. Poly-unsaturated fatty acids: their cellular role and clinical applications (Part I). The Medicine Journal (SA) 2001;43:13-7.
19. Erasmus U. Fats that heal, fats that kill. 3rd ed. Burnaby (BC): Alive Books; 1993.
20. Marteinsdottir I, Horrobin DF, Stenfors C, Theodorsson E, Mathé AA. Changes in dietary fatty acids alter phospholipid fatty acid composition in selected regions of rat brain. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1007-21.
21. Quoc KP, Pascaud M. Effects of dietary γ-linolenic acid on the tissue phospholipid fatty acid composition and the synthesis of eicosanoids in rats. Ann Nutr Metab 1996;40:99-108.
22. Haag M. Poly-unsaturated fatty acids: their cellular role and clinical applications (Part II). The Medicine Journal (SA) 2002;44:30-4.
23. Simopoulos AP. omega-3 Fatty acids and human health: defining strategies for public policy. Lipids 2001;36(Suppl):S83-S89.
24. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, aging and osteoporosis. Prostaglandins Leukot Essent Fatty Acids 1999;60:217-34.
25. Horrobin DF, Bennett CN. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids 1999;60:141-67.
26. Van Rooyen JM, Offermeier J, Stahmer SD. Serotonin receptors. The Medicine Journal (SA) 1991;33:3-19.
27. Garcia-Sanz JA, Vazquez-Prado J, Villalobos-Molina R. Alpha-1-adrenoceptors: subtypes, signaling, and roles in health and disease. Arch Med Res 1999;30:449-58.
28. Popoli M, Brunello N, Perez J, Racagni G. Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J Neurochem 2000;74:21-33.
29. Salem N Jr, Litman B, Kim H-Y, Gawrisch K. Mechanism of action of docosahexaenoic acid in the nervous system. Lipids 2001;9:945-59.
30. Murphy MG. Membrane fatty acids, lipid peroxidation and adenylate cyclase activity in cultured neural cells. Biochem Biophys Res Commun 1985;132:757-63.
31. Nicolas C, Lacasa D, Guidicelli Y, Demarne Y, Agli B, Lecourtier MJ, and others. Dietary (omega-6) poly-unsaturated fatty acids affect β-receptor binding and adenylate cyclase activity in pig adipocyte plasma membranes. J Nutr 1991;121:1179-86.
32. Speizer LA, Watson MJ, Brunton LL. Differential effects of omega-3 fish oils on protein kinase activities in vitro. Am J Physiol 1991;261:E109-E114.
33. Irvine RF, Letcher AJ, Dawson RMC. Fatty acid stimulation of membrane phosphatidylinositol hydrolysis by brain phosphatidylinositol phosphodiesterase. Biochem J 1979;178:497-500.
34. 2+-dependent protein kinase. Science 1984;224:622-5.
35. 2 and the effects of arachidonic acid. J Biol Chem 1988;263:7506-13.
36. Shukla SD, Halenda SP. Phospholipase D in cell signalling and its relationship to phospholipase C. Life Sci 1991;48:851-66.
37. Downes CP, Currie RA. Lipid signalling. Curr Biol 1998;8:R865-R867.
38. 2. J Neurochem 1995;64;2765-72.
39. Berg KA, Maayani S, Clarke WP. 5-Hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamineIB-like receptor function via arachidonic acid metabolism. Mol Pharmacol 1996;5:1017-23.
40. Tence M, Murphy N, Cordier J, Premont J, Glowinski J. Synergistic effects of acetyl choline and glutamate on the release of arachidonic acid from cultured striatal neurons. J Neurochem 1995;64:1605-13.
41. Jones CR, Arai T, Bell JM, Rapoport SI. Preferential in vivo incorporation of [3H] arachidonic acid from blood into rat brain synaptosomal fractions before and after cholinergic stimulation. J Neurochem 1996;67:822-9.
42. Piomelli D. Eicosanoids in synaptic transmission. Crit Rev Neurobiol 1994;8:65-83.
43. Smith WL. Prostanoid synthesis and mechanisms of action. Am J Physiol 1992;263:F181-F191.
44. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of 1-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1997;94:4182-7.
45. Wieland SJ, Fletcher JE, Gong QH. Differential modulation of a sodium conductance in skeletal muscle by intracellular and extracellular fatty acids. Am J Physiol 1992;263:C308-C312.
46. 2+/calmodulin-dependent protein kinase II by arachidonic acid and its metabolites. Proc Natl Acad Sci USA 1989;86:8550-4.
47. Kearns SD, Haag M. The effect of omega-3 fatty acids on Ca-ATPase in rat cerebral cortex. Prostaglandins Leukot Essent Fatty Acids 2002;67:303-8.
48. Delion S, Chalon S, Hérault J, Guilloteau D, Besnard JC, Durand G. Chronic dietary α-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. J Nutr 1994;124:2466-76.
49. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G. α-Linolenic acid deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 1996;66:1582-91.
50. Chalon S, Delion-Vancassel S, Belzung C, Guilloteau D, Leguisquet AM, Besnard JC, and others Dietary fish oil affects monoaminergic neurotransmission and behaviour in rats. J Nutr 1998;128:2512-9.
51. Zimmer L, Hembert S, Durand G, Breton P, Guilloteau D, Besnard JC, and others Chronic omega-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci Lett 1998;240:177-81.
52. Zimmer L, Durand G, Guilloteau D, Chalon S. Omega-3 Polyunsaturated fatty acid deficiency and dopamine metabolism in the rat frontal cortex. Lipids 1999;34:S251.
53. De la Presa Owens S, Innis SM. Docosahexaenioc and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotransmitters in frontal cortex caused by a linoleic and α-linolenic acid deficient diet in formula-fed piglets. J Nutr 1999;129:2088-93.
54. Yoshida S, Yasuda A, Kawazato H, Sakai K, Shimada T, Takeshita M, and others. Synaptic vesicle ultrastructural changes in the rat hippocampus induced by a combination of α-linolenate deficiency and a learning task. J Neurochem 1997:68:1261-8.
55. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, and others. Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 1997;58:1123-9.
56. Carlson SE. Growth and development of premature infants in relation to w3 and w6 fatty acid status. World Rev Nutr Diet 1990;75:63-9.
57. Carlson SE, Werkman SH. A randomised trial of visual attention of preterm infants fed docosahexanoic acid for 2 months. Lipids 1996;31:85-90.
58. Carlson SE, Tolley E. Effect of long-chain omega-3 fatty acid supplementation on visual acuity and growth of preterm infants with and without bronchopulmonary dysplasia. Am J Clin Nutr 1996;63:687-97.
59. Carlson SE. Lipid requirements of very low birth weight infants for optimal growth and development. In: Dobbing J, editor. Lipids, learning, and the brain: fats in infant fomulas. Columbus (OH): Ross Laboratories; 1993. p 188-207.
60. Agostini C, Trojan S, Bellu R, Riva E, Giovannini M. Neurodevelopmental quotient of healthy term infants and feeding practice: the role of polyunsaturated fatty acids. Pediatr Res 1995;38:262-6.
61. Hoffman DR, Birch EE, Birch DG, Uauy R. Fatty acid profile of buccal cheek phospholipids as an index for dietary intake of docosahexanoic acid in preterm infants. Lipids 1999;34:337-42.
62. Birch E, Hoffman D, Uauy R, Birch D, Prestidge C. Visual acuity and the essentiality of docosahexanoic acid and arachidonic acid in the diet of term infants. Pediatr Res 1998;44:201-9.
63. Willats P, Forsyth JS, DiModugno MK, Varma S, Colvin M. Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 1998;352:688-91.
64. Slater A. Individual differences in infancy and later IQ. J Child Psychol Psychiatry 1995;36:69-112.
65. Scott DT, Janowsky JS, Carroll RE, Taylor JA, Auestad N, Monalto MB. Formula supplementation with long-chain polyunsaturated fatty acids: are there developmental benefits? Pediatrics 1998;102:59. (electronic publication).
66. Burgess JR, Stevens L, Zhang W, Peck L. Long chain polyunsaturated fatty acids in children with attention deficit hyperactivity disorder. Am J Clin Nutr 2000;71:327S-330S.
67. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird W. A randomized, double-blind, placebo-controlled trial of docosahexanoic acid supplementation in children with attention deficit/hyperactivity disorder. J Pediatr 2001;139:173-4.
68. Maes M, Christophe A, Bosmans E, Lin A, Neels H. In humans, serum polyunsaturated fatty acid levels predict the response of pro-inflammatory cytokines to psychological stress. Biol Psychiatry 2000;47:910-20.
69. 1 in the affective disorders and metabolism. BMJ 1980;280:1363-6.
70. Hibbeln JR, Salem N Jr. Dietary polyunsaturated fats and depression: when cholesterol alone doesn't satisfy. Am J Clin Nutr 1995;62:1-9.
71. Lavori PW, Warshaw M, Klerman G, Mueller TI, Leon A, Rice J, and others. Secular trends in lifetime onset of MDD stratified by selected sociodemographic risk factors. J Psychiatr Res 1993;27:95-109.
72. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic to eicosapentanoic acid ratio in blood correlates positively with symptoms of depression Lipids 1996;31 (Suppl):S157-S161.
73. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acids levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998;48:149-55.
74. Maes M, Smith RS. Fatty acids, cytokines and major depression. Biol Psychiatry 1998;43:313-4.
75. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;22:85:275-91.
76. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond A, and others. Omega-3 Fatty acids in bipolar disorder. Arch Gen Psychiatry 1999;56:401-12.
77. Ellis FR, Sanders TAB. Long chain polyunsaturated fatty acids in endogenous depression. J Neurol Neurosurg Psychiatry 1977;40:168-9.
78. Fehily AMA, Bowey OAM, Ellis FR, Meade BW, Dickerson JWT. Plasma and erythrocyte membrane long chain polyunsaturated fatty acids in endogenous depression. Neurochem Int 1981;3:37-42.
79. Mellor J, Laugharne J, Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Hum Psychopharmacol 1996;11:39-46.
80. Peet M, Mellor J. Double blind placebo-controlled trial of omega-3 polyunsaturated fatty acids as an adjunct to neuroleptics. Schizophr Res 1998;29:160.
81. Yao JK, Van Kammen DP, Gurklis J. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 1994;13:227-32.
82. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000;42:7-17.
83. Peet M, Horrobin DF, E-E Multicentre study group. A dose-ranging exploratory study of the effects of ethyl-eicosapentanoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002;36;7-18.
84. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebocontrolled trial of omega-3 fatty acid (ethyl eicosapentanoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001;158:2071-4.
85. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid (fish or evening primrose oil) for schizophrenia. Cochrane Database Syst Rev 2000;2:1-28.
86. Swank RL, Lerstad O, Strom P, Barker J. Multiple sclerosis in rural Norway: its geographic and occupational incidence in relation to nutrition. N Engl J Med 1952;246:721-8.
87. Holman R, Johnson S, Kokmen E. Deficiencies of polyunsaturated fatty acids and replacement by non-essential fatty acids in plasma lipids in multiple sclerosis. Proc Natl Acad Sci USA 1989;86:4720-4.
88. Gallai V, Sarchielli V, Trequattrini A, Franceschini M, Floridi A, Firenzi C, and others. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with omega-3 fatty acids. J Neuroimmunol 1995;56:143-53.
89. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and omega-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000;102:143-9.
90. Zhang SM, Willett WC, Hernán MA, Olek MJ, Ascherio A. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am J Epidemiol 2000;152:1056-106.
91. Horrobin DF. Loss of delta-6-desaturase activity as a key factor in aging. Med Hypotheses 1981;7:1211-20.
92. Maniongui C, Blond JP, Durand G, Poisson JP, Bezard J. Age-related changes in D6 and D5 desaturase activities in rat liver microsomes. Lipids 1993;28:291-7.
93. McGeer PL, McGeer EG. The inflammatory response system of the brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
94. Markesby WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23:134-47.
95. Lonergan PE, Martin DS, Horrobin DF, Lynch MA. Neuroprotective effect of eicosapentanoic acid in hippocampus of rats exposed to gamma-irradiation. J Biol Chem 2002;277:20804-11.
96. McGahon BM, Martin DSD, Horrobin DF, Lynch MA. Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 1999;94:305-14.
97. Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI. Essential fatty acids preparation (SR-3) improves Alzheimer's patients' quality of life. Int J Neurosci 1996;87:141-9.
98. Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, and others. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002;13:123-6.
99. Sanders TAB. Polyunsaturated fatty acids in the food chain in Europe. Am J Clin Nutr 2000;71(Suppl):176S-178S.